RxTally.CA — Canadian maple leaf logoClarity in every comparison.
Coverage · Canada

Is Mounjaro covered in Canada?

Short answer: not yet, publicly — but the national drug agency said yes in August 2026, and provinces are now deciding. Private insurance is the main route today, and only for type 2 diabetes.

By RxTallyLast Update 6 min read

The quick answer

Public coverage: no — not yet. As of October 2026, no provincial public drug plan lists Mounjaro. British Columbia has it under review. Canada's Drug Agency recommended public coverage for type 2 diabetes on August 24, 2026, with price conditions attached, so listings are now possible — but a recommendation is not a listing, and none has been confirmed.

Private insurance: often yes for type 2 diabetes, with prior authorization. Rarely for weight loss — Mounjaro is approved in Canada for diabetes only, and weight-management use is off-label.

Without coverage: roughly $326–$750 a month depending on dose and pharmacy. Lilly advertises a self-pay starting estimate of $300 per 28 days for the 2.5 mg or 5 mg KwikPen, excluding dispensing fees.

1. Three things decide your coverage

Before you look anything up, know that the answer turns on three questions — and the same prescription can get three different answers:

  1. What is it prescribed for? Type 2 diabetes and chronic weight management are different coverage decisions, even though the drug is the same molecule. Mounjaro is Health Canada-approved for type 2 diabetes only; the on-label tirzepatide for weight management is Zepbound.
  2. Which province are you in? Each province runs its own formulary with its own authorization rules — and right now they are all at different stages of deciding.
  3. Which plan? Public coverage depends on which provincial program you qualify for; private coverage depends on your specific employer's plan design, not just the insurer's name.

2. The news: Canada's Drug Agency said yes — with strings

The reason this question has a different answer than it did a year ago is a single document. On August 24, 2026, Canada's Drug Agency (CDA-AMC) published its final reimbursement recommendation for tirzepatide (Mounjaro): public drug plans should reimburse it as an add-on to diet and exercise for adults with type 2 diabetes, when combined with metformin, metformin plus a sulfonylurea, or metformin plus an SGLT2 inhibitor — if certain conditions are met.

The conditions matter more than the headline:

  • Same patients as semaglutide. Coverage should only extend to patients who would already meet the criteria public plans use for other GLP-1 drugs like Ozempic. Mounjaro doesn't open a new door; it joins the existing one.
  • Not in combination. It should not be used together with other GLP-1 drugs.
  • Price. The 5 mg dose must cost public plans no more than semaglutide 1 mg, and the 10 mg and 15 mg doses must be reduced. The earlier draft suggested discounts of 25–49% off list at higher doses; the final recommendation states the price must come down without naming a figure. Budget impact must also be addressed before health systems can adopt it.

For scale: Mounjaro's list price was $300–$540 for a four-week supply as of early 2026, depending on dose, versus about $228 for Ozempic.

A recommendation is not a listing. CDA-AMC advises; each province then negotiates price (through the pan-Canadian Pharmaceutical Alliance) and decides whether to list the drug on its own formulary. That sequence takes months. It is why the honest answer in October 2026 is "not yet" — and why it could change in 2027.

3. Public coverage by province

Unlike Ozempic, which every province lists for type 2 diabetes, Mounjaro has no confirmed public listing anywhere in Canada. The table below says what we could verify — and where we could not.

Province / programType 2 diabetesStatusWeight loss
Ontario — Ontario Drug Benefit (ODB)Not listedA formulary search for tirzepatide returns no products. Trillium can't help either — it only covers drugs on the ODB formulary.Not covered
British Columbia — PharmaCareUnder reviewBC's own Drug Information Sheet lists Mounjaro's PharmaCare status as "Under Review." Public input ran February 25 to March 24, 2026. It is not a benefit yet.Not covered
Alberta — Alberta Drug Benefit ListNot coveredNo listing found. Maple's September 2026 review also states Alberta has no provincial coverage for Mounjaro.Not covered
Saskatchewan — Drug PlanNot confirmedNo public listing found. Treat as not covered until the formulary shows otherwise.Not covered
Manitoba — Drug Benefits FormularyNot confirmedNo public listing found. Treat as not covered until the formulary shows otherwise.Not covered
Quebec — RAMQNot listedRAMQ does not list Mounjaro. Quebec's drug-review body, INESSS, still has a Mounjaro listing request open — for pediatric type 2 diabetes — marked "awaiting reply" as of October 9, 2026.Not covered
Atlantic Canada (NS, NB, PEI, NL)Not confirmedNo public listing found in any Atlantic formulary. Confirm with your provincial plan.Not covered
Federal — NIHB (First Nations and Inuit)Not confirmedWe could not confirm an NIHB listing for Mounjaro. Ask your provider or pharmacist to check the NIHB formulary.Not covered

Formulary listings change — and for Mounjaro they are likely to change soon. Before relying on a row above, confirm the current listing in your province's formulary; the references are listed below.

Why some websites say Mounjaro is already covered

A few price-comparison sites currently claim Mounjaro is a Limited Use benefit in Ontario, or has Special Authority in BC. We could not confirm either claim against any formulary record or ministry document — and BC's own Drug Information Sheet says the opposite: "Under Review." The Ontario claims also predate the August 2026 national recommendation that would normally come first. Until a provincial formulary shows it, we treat Mounjaro as not publicly covered. If a listing lands, this page will be updated.

OHIP doesn't pay for drugs

A common confusion: OHIP covers doctor visits and hospital care, not outpatient prescriptions. In Ontario, drug coverage comes from the Ontario Drug Benefit program — for seniors, youth, social assistance recipients, and households in the Trillium Drug Program. If someone asks "is Mounjaro covered by OHIP?", the accurate answer is that OHIP itself doesn't cover it; ODB might, if you're eligible — and right now Mounjaro isn't on the ODB formulary at all.

4. What it costs without coverage

With no public plan paying, the full retail price lands on you — or on your private plan. Mounjaro runs roughly $326–$750 a month depending on dose and pharmacy: phone quotes from Ontario pharmacies in June 2026 put the 2.5 mg and 5 mg KwikPens at $325.67 at Costco and around $360–$366 at Shoppers and Rexall, rising to $582–$650 at the 15 mg dose. Maple's post-reduction band, after a price cut that took effect December 29, 2025, is $405–$750 a month. Mounjaro is now KwikPen-only in Canada — the single-dose vials have been discontinued.

Three things soften the bill, none of them a public plan:

  • The MyMounjaro savings card. Lilly’s public program offers a savings card with or without another plan. Its self-pay starting estimate is $300 per 28 days for the 2.5 mg or 5 mg KwikPen, excluding dispensing fees. The amount depends on pharmacy pricing and eligibility. Confirm the public-plan and province-specific rules before budgeting. See our savings-cards guide.
  • The medical expense tax credit. Out-of-pocket prescription costs count as eligible medical expenses. For the 2026 tax year, the federal threshold is the lesser of $2,834 or 3% of net income — a full year of Mounjaro easily clears it for most people. Keep every pharmacy receipt.
  • There is no generic. Unlike semaglutide, which has authorized generics from about $88 a pen, tirzepatide remains under patent into the 2030s. There is no cheap generic floor to fall back on — the price you see is the price.

Run your own numbers in our total-cost calculator, which models the Ontario public, private, and no-insurance paths.

5. Private insurance: plan-specific, and diabetes only

Private coverage is where most Mounjaro patients actually get help — but the indication decides everything:

  • For type 2 diabetes, many group plans cover Mounjaro with prior authorization. Insurer diabetes forms list Mounjaro alongside Ozempic, Rybelsus, Victoza and Trulicity, and the clinical criteria mirror those for other GLP-1 drugs — the same logic CDA-AMC used in its recommendation. Your prescriber submits the form; approval is not automatic, and the plan will want evidence of prior therapy, typically a metformin trial.
  • For weight management, coverage is effectively closed. Canada Life states that Ozempic, Rybelsus and Mounjaro are not covered for chronic weight management, and Mounjaro's Health Canada approval doesn't include weight loss at all — that use is off-label. If weight management is the goal, the on-label tirzepatide is Zepbound, and it faces the same optional-benefit test: your employer must have chosen to include weight-management drugs in the plan.

Private plans that do cover weight-management drugs usually require prior authorization — typically a BMI of 30 or more, or 27 or more with a weight-related condition, plus documented diet and activity, with renewal requiring at least 5% weight loss maintained. Exact criteria vary by insurer and plan, and they apply to the weight-management products (Wegovy, Zepbound, Saxenda), not to Mounjaro.

6. Mounjaro vs Ozempic vs Zepbound — the coverage contrast

The three drugs get confused constantly, and coverage is where they split apart:

DrugApproved forPublic coverage, type 2 diabetesPublic coverage, weight loss
Ozempic (semaglutide)Type 2 diabetesListed in every provinceNot covered
Mounjaro (tirzepatide)Type 2 diabetesRecommended Aug 2026 — not yet listedNot covered (off-label use)
Zepbound (tirzepatide)Chronic weight management—Not covered

Mounjaro and Zepbound are the same molecule, tirzepatide, sold under two names for two indications. Plans treat them as different drugs: a private plan that covers Mounjaro for diabetes will not necessarily cover Zepbound for weight management, and vice versa. Ask about the brand name and the DIN, not just "tirzepatide."

7. When it's not covered — your options

  • Apply for the savings card first. MyMounjaro is the one manufacturer program that applies to Mounjaro, and it works with or without private insurance. Enrol through Lilly (1-833-382-8639) before your first fill — it applies to the amount you owe after insurance.
  • Push the prior authorization through. If your private plan covers diabetes drugs but hasn't added Mounjaro yet, ask your prescriber to submit the authorization form with your A1C, BMI, and prior-therapy history. A prescriber letter explaining why tirzepatide specifically is appropriate can help on appeal.
  • Ask about the generic semaglutide alternative. If cost is the barrier and the indication is type 2 diabetes, generic semaglutide is publicly covered and runs about $88–$103 a pen — a different drug, so this is a prescriber conversation, not a pharmacy swap. See our generic semaglutide tracker.
  • If a claim is declined, get the reason in writing. An exclusion, a missing authorization, and an unmet clinical criterion are three different problems with three different next steps — including an appeal. Our coverage guide walks through the process.
  • Watch the formularies. The CDA-AMC recommendation is the trigger that starts provincial listings. When Ontario or BC lists Mounjaro, the public-coverage answer flips — check back, or check your province's formulary directly.

8. How to check your own coverage

The script

"I'm checking coverage before filling a prescription. The medication is Mounjaro, DIN [number], prescribed for type 2 diabetes. Is it covered under my plan for that indication, does it need prior authorization, and what would I pay after my deductible?"

Give the insurer the DIN, not just the brand name — plans decide by DIN. Mounjaro KwikPen DINs run 02551950–02552000; find yours in our DIN guide.

  1. Check the formulary first — your province's list tells you whether the drug is listed and under what mechanism. For Mounjaro, expect "not listed" or "under review" for now.
  2. Check your plan — your benefits booklet or member portal, using the DIN. For Sun Life members, the signed-in Drug lookup tool shows whether authorization is needed.
  3. Ask in writing — get the decision, the authorization form, the deductible and maximum, and the renewal rules in writing before your first fill.
  4. Ask about retroactivity — if you pay while an application is pending, ask whether approval would reimburse earlier purchases. Don't budget on it.

Frequently asked questions

Is Mounjaro covered by OHIP?

No. OHIP covers medical services, not outpatient prescriptions. Drug coverage in Ontario comes from the Ontario Drug Benefit program — and Mounjaro is not on the ODB formulary at all, so there is currently no public route to coverage in Ontario for either indication.

Is Mounjaro covered for weight loss in Canada?

No. No provincial public plan covers any drug for weight management except in the narrowest cases, and Mounjaro isn't approved for weight loss in Canada — that use is off-label. The on-label tirzepatide for weight management is Zepbound, which is also not publicly covered. Private coverage for weight management exists only where the employer specifically included it.

Will Mounjaro be covered soon?

Possibly, for type 2 diabetes. Canada's Drug Agency recommended public coverage on August 24, 2026, with price conditions — the 5 mg dose must cost no more than semaglutide 1 mg, and higher doses must be reduced. Provinces now negotiate price and decide on listing, which typically takes months. BC already has it under review. There is no timeline for weight-loss coverage, which no province offers for any GLP-1 drug.

Does private insurance cover Mounjaro?

Often, for type 2 diabetes — with prior authorization, and depending on your specific plan. Many group plans list Mounjaro on their diabetes authorization forms. For weight management, generally no: Canada Life states Mounjaro is not covered for chronic weight management, and the use is off-label. Check your own plan with the DIN.

Is Mounjaro covered in BC or Alberta?

Not yet in either. BC PharmaCare lists Mounjaro as "Under Review" — its Drug Information Sheet went out for public input in February–March 2026, and no coverage decision has been announced. Alberta has no listing; Maple's September 2026 review states Alberta has no provincial coverage for Mounjaro.

Mounjaro vs Zepbound — which one is covered?

Neither is publicly covered. They are the same molecule, tirzepatide, under two brand names: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Mounjaro has a national recommendation for public diabetes coverage (August 2026) and may be listed first. Privately, a plan may cover one and not the other — ask about the brand name and DIN, not just "tirzepatide."

Sources

Canada's Drug Agency — Tirzepatide (Mounjaro) reimbursement recommendation, Canadian Journal of Health Technologies, published August 24, 2026 (reimburse for type 2 diabetes with conditions: same criteria as other GLP-1 RAs; not in combination with other GLP-1 RAs; 5 mg cost not to exceed semaglutide 1 mg; 10 mg and 15 mg reduced) · BC PharmaCare — Drug Information Sheet for tirzepatide (Mounjaro) (status "Under Review"; public input February 25–March 24, 2026; Ozempic listed as Limited Coverage) · INESSS — drugs under evaluation (Mounjaro listing request for pediatric type 2 diabetes, "awaiting reply," October 9, 2026) · Middleway Nutrition — GLP-1 in Canada 2026 (May 2026: "Mounjaro is not an ODB benefit — a formulary search for tirzepatide returns no products at all") · Maple — How Much Does Mounjaro Cost in Canada? (September 2026: no provincial coverage; $405–$750/month after the December 29, 2025 price reduction; KwikPen-only, vials discontinued; no generic tirzepatide) · TeleTest — Mounjaro Cost in Canada (June 2026 phone quotes: $325.67–$650/month including dispensing fee) · Medical Weight Loss Canada — prior authorization forms (Canada Life: Ozempic, Rybelsus and Mounjaro not covered for chronic weight management; Medavie diabetes form covers Mounjaro) · Eli Lilly Canada — MyMounjaro program (card with or without another plan; self-pay starting estimate $300 per 28 days for 2.5 mg or 5 mg KwikPen; dispensing fees excluded). Two secondary sources (semaglutidecanada.com, teletest.ca) claim Ontario Limited Use / BC Special Authority for Mounjaro; neither claim could be confirmed against a formulary record or ministry document, and BC's own sheet contradicts the Special Authority claim — this article treats Mounjaro as not publicly covered until a formulary shows otherwise.

This article explains coverage rules; it is not medical advice and does not determine your benefits. Formulary listings and plan rules change — confirm your own coverage with your provincial program and insurer before filling a prescription. Medical disclaimer · Methodology